The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials

(2014) Pablo Tebas et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir

(2014) Thomas N. Kakuda et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

(2014) Nicholas I. Paton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

(2013) Allison Martin et al.   AIDS

The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients

(2013) Antonio Biagio et al.   CURRENT HIV RESEARCH

Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

(2013) Babafemi Taiwo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

(2013) Allison Martin et al.   PLoS One

Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA

(2012) Eoin R. Feeney et al.   AIDS

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

HIV-1 Antiretroviral Resistance

(2012) Michele W. Tang et al.   DRUGS

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

(2011) Babafemi Taiwo et al.   AIDS

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients

(2011) Brian Gazzard et al.   AIDS

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

(2010) Edwin DeJesus et al.   ANTIVIRAL THERAPY

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Human Immunodeficiency Virus Treatment–Induced Adipose Tissue Pathology and Lipoatrophy: Prevalence and Metabolic Consequences

(2010) Emma Hammond et al.   CLINICAL INFECTIOUS DISEASES

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial*

(2010) AB Hansen et al.   HIV MEDICINE

Insulin Sensitivity in Multiple Pathways Is Differently Affected During Zidovudine/Lamivudine-Containing Compared With NRTI-Sparing Combination Antiretroviral Therapy

(2010) Marit G A van Vonderen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

(2009) Marit GA van Vonderen et al.   AIDS

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

(2008) Sharon A. Riddler et al.   NEW ENGLAND JOURNAL OF MEDICINE